12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lonquex lipegfilgrastim regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA from Teva for Lonquex lipegfilgrastim to prevent chemotherapy-induced neutropenia. Lonquex is recommended to...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >